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Background: NKG2D (natural killer group 2, member D) is thought to play an important role in mediating the
activation of anticancer immune response. Expression of NKG2D ligands (NKG2DLs) is pronounced in malignancies
and the heterogeneity of NKG2DL expression remains unclear. Here, we investigate the expression and clinical
significance of NKG2DLs in cervical cancer.
Methods: Immunohistochemical analyses of MICA/B, ULBP1, ULBP2, ULBP3, RAET1E, and RAET1G were performed
using tissue microarray analysis of 200 cervical cancers, 327 high-grade cervical intraepithelial neoplasias (CINs), 99
low-grade CINs, and 541 matched nonadjacent normal cervical epithelial tissues and compared the data with
clinicopathologic variables, including the survival of cervical cancer patients.
Results: MICA/B, ULBP1, and RAET1E expression was higher in cervical cancer than in low-grade CIN (p < 0.001,
p = 0.012, p = 0.013, respectively) and normal cervix (all p < 0.001). Among these markers, expression of ULBP1 was
significantly different depending on patient tumor stage (p = 0.010) and tumor size (p = 0.045). ULBP1 expression
was correlated with MICA/B (p < 0.001) and ULBP2 (p = 0.002) expression in cervical cancer. While MICA/B+ or
ULBP1+ patients had improved disease-free survival time (p = 0.027 and p = 0.009, respectively) relative to that of
the low expression group, RAET1E+ or RAET1G+ was correlated with shorter survival time (p = 0.018 and p = 0.029,
respectively). However, in terms of overall survival, the ULBP1+ group had significantly longer survival time than the
low expression group (p = 0.009). Multivariate analysis indicated that MICA/B+/ULBP1+ (HR = 0.16, p = 0.015) and
ULBP1+ (HR = 0.31, p = 0.024) are independent prognostic factors of disease-free survival in cervical cancer.
Conclusions: High expression of either ULBP1 or MICA/B and ULBP1 combined is an indicator of good prognosis
in cervical cancer, suggesting their potential utility as prognostic tests in clinical assessment.
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Cervical cancer is the second most common malignant
tumor affecting women worldwide, causing an estimated
273,200 deaths annually, and is the most common tumor
in developing countries [1]. Persistent infection with one
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unless otherwise stated.types 16 and 18) has been shown to be a major etiological
factor of HPV-related premalignant lesions and cervical
cancer [2]. Although the vast majority of cervical cancers
are derived from cervical intraepithelial neoplasia (CIN),
the majority of genital HPV infections are clinically
undetectable and clear in 10–16 months; only a very small
proportion progress into an invasive cervical cancer.
It is well known that persistent HPV infection causes
progression from low-grade CIN to high-grade CIN, and
eventually to a malignant cervical cancer in a multistep
process [3-5]. The progression of these lesions may be due
to an adverse tumor environment, wherein the mucosalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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malignant cells.
Host immune response to HPV appears to be critical
in determining the outcome of infection. For example,
among immunocompromised women, HPV infection is
detected more frequently, the incidence of CIN is higher,
and the risk of CIN recurrence after treatment is higher [6].
Innate immune response is thought to be the first line
of defense at mucosal surfaces. Natural killer (NK) cells
are important cytolytic and cytokine-producing effector
cells of the innate immune system. These cells have
the ability to attack tumor cells and cells infected with
viruses and some bacteria without presentation of tumor-
specific antigens [7]. Furthermore, intratumoral NK cell
accumulation has been correlated with improved survival
rates in patients with various solid tumors [8,9]. In the
case of cervical cancer, Garzetti et al. reported that NK
cell activity was related to prognostic parameters and
clinical outcome [10].
NKG2D (natural killer group 2, member D) is a C-type
lectin-like activating receptor expressed on the surface of
NK cells and a variety of T cell subsets including
CD8+ cytotoxic T cells [11]. Human NKG2D ligands
(NKG2DLs) consist of two members of the MHC
class I-related chain (MIC) family (MICA and MICB) and
six members of the UL16 binding protein or retinoic acid
early transcript (ULBP/RAET) family (ULBP1, ULBP2,
ULBP3, RAET1E, RAET1G, and RAET1L) [12]. NKG2DL
expression is highly restricted in healthy tissues, but can
be stimulated by multiple stimuli, including infection and
heat shock, and by cellular transformation [12]. It is also
broadly expressed in a variety of tumors, including
hematologic and epithelial malignancies [12,13], cervical
cancers [14], and cancer cell lines [15,16]. The mechanisms
regulating NKG2DL expression in carcinogenesis still
remain to be elucidated, although activation of DNA
damage response pathways and expression of the BCR/ABL
oncogene have been implicated [16-18].
In the current study, we hypothesized that the expression
of some or all types of NKG2DLs in cervical neoplasias are
correlated with tumor progression. To explore this hypoth-
esis, we investigated the expression of MICA/B, ULBP1,
ULBP2, ULBP3, RAET1E, and RAET1G in normal cervical
epithelium and cervical neoplasia in a large series of
formalin-fixed, paraffin-embedded tumor samples made by
using high-throughput tissue microarray (TMA) technology.
Because HPV is associated with cervical carcinogenesis, we
also examined the relationship between HPV status and
NKG2DL expression in cervical neoplasia.
Methods
Patients and tumor samples
The study subjects were comprised of 200 cervical cancer
and 426 cervical intraepithelial neoplasias (CINs) patientswho underwent surgical resection at Gangnam Severance
Hospital, Yonsei University College of Medicine between
March 1996 and March 2010. Additional paraffin blocks
were provided by the Korea Gynecologic Cancer Bank
through the Bio & Medical Technology Development
Program of the Ministry of Education, Science and
Technology, Korea. All patients had a histological diagnosis
of cervical carcinoma or CIN, and the cervical cancer
patients were clinically staged according to the International
Federation of Gynecology and Obstetrics (FIGO) staging
system. Patients with cervical cancer underwent type 3 rad-
ical hysterectomy with pelvic lymph node dissection, and, in
cases of increased risk of relapse (assessed from spread to
lymph node, parametrial invasion, and cancer close to resec-
tion margins), platinum-based concurrent chemoradiation
was added. Medical records were reviewed to obtain data
including age, Hybrid Capture® 2 results, surgical procedure,
survival time, and survival status. Response to therapy was
assessed by either computed tomography or magnetic res-
onance imaging in accordance with the Response Evaluation
Criteria in Solid Tumors (RECIST, version 1.0) [17]. Data
on tumor size, cell type, tumor grade, and lymph node me-
tastases were obtained from pathology reports. Tissue sam-
ples were collected from patients who had signed informed
consent forms, which was approved by the Institutional
Review Boards of Gangnam Severance Hospital. This study
was additionally approved by the Office of Human Subjects
Research at the National Institute of Health.
Tissue microarray construction
Tissue cores, from formalin-fixed, paraffin-embedded tissue
blocks obtained from 626 patients with primary invasive
cervical cancer or CIN and 541 matched nonadjacent
normal cervical epithelia were arrayed into a recipient
paraffin block with a manual tissue arrayer MTA-1
(Beecher Instruments Inc., Silver Spring, MD). These
normal cervical tissue cores were obtained from the
same block at locations distant from the cancer cells
or from different block that contained enough normal
epithelial cells for further IHC analyses. For each case, a
representative tumor area was carefully selected from a
hematoxylin and eosin (H&E)-stained section of the donor
block. Four 1.0-mm-diameter cores consisting of matched
tumor specimen and normal epithelial samples were
retrieved from selected regions of a patient’s donor
block. The presence of tumor tissues on the tissue
microarray (TMA) was verified with H&E staining. At
every 50th section, multiple 5-μm-thick sections were
cut with a microtome and H&E staining of TMA slides
were examined for the presence of tumor cells.
Cell culture
Human cervical cancer cell lines were obtained from two
sources: C-33A, CaSki, HeLa, ME-180 and SiHa from
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VA) and SUN-17 from Korean Cell Line Bank (KCLB,
Seoul, Korea). CaSki, HeLa, ME-180, and SUN-17 cells
were cultured in vitro in RPMI 1640 while C-33A
and SiHa cells were cultured in DMEM (Dulbecco’s
modified Eagle’s medium). Both media were supplemented
with 10% fetal bovine serum, 50 units/ml of penicillin/
streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate,
and 2 mM non-essential amino acids, and cells were
grown at 37°C with 5% CO2.
Flow cytometry analysis
For in vitro flow cytometry analysis, 2 × l05 tumor cells
were incubated with 0.5 μg recombinant human NKG2D
Fc chimera (R & D systems, Minneapolis, MN) and then
PE-conjugated anti-human Fc secondary antibody was
used as a detection antibody (BD Bioscience, San
Jose, CA). CELLQuest software (Becton Dickinson
Immunocytometry System, Mountain View, CA) was
used for FACScan analysis.
Immunohistochemistry
Immunohistochemical staining of MICA/MICB, ULBP1,
ULBP2, ULBP3, RAET1E, and RAET1G was performed
by using streptavidin-biotin peroxidase method. Prior to
applying IHC with TMA section, we tested whole
section for immunohistochemial staining condition. Briefly,
the TMA sections were deparaffinized by xylene and then
rehydrated through a descending alcohol gradient.
Endogenous peroxidase activity was blocked by 10 min of
incubation in 3% H2O2. To retrieve antigenicity, sections
were immersed in antigen retrieval buffer, pH 9 (Dako,
Carpinteria, CA), and heated for 20 min in a steam
pressure cooker (Pascal, Dako). Slides for ULBP1 and
ULBP2, however, were heated for 10 min instead of
20 min at high pressure. To block nonspecific staining,
sections were treated with Protein Block (Dako) for
20 min. The sections were incubated with anti-MICA/
MICB antibody (Novus Biologicals, Littleton, CO; mouse
monoclonal antibody, Clone 6D4, 1:50 for 120 min),
anti-ULBP1 antibody (Sigma-Aldrich, St. Louis, MO;
rabbit polyclonal antibody, Cat.# HPA007547, 1:50 for
120 min), anti-ULBP2 antibody (R&D systems; goat
polyclonal antibody, Cat.# AF1298, 1:50 for 30 min),
anti-ULBP3 antibody (Abcam, Cambridge, MA; mouse
monoclonal antibody, Clone MM0594-6E12, 1:500 for
120 min), anti-RAET1E antibody (Novus Biologicals;
mouse polyclonal antibody, Cat.# H00135250-B01, 1:2000
overnight at 4°C), and anti-RAET1G antibody (Novus
Biologicals; mouse polyclonal antibody, Cat.# H00353091-
B01, 1:1000 overnight at 4°C) in a Dako autostainer plus
(Dako). Different systems were used for the detection
of primary antibodies: Dako EnVision + Dual Link
System-HRP (Dako) for MICA/MICB and ULBP3; DakoEnVision FLEX+ (Dako) for ULBP1, RAET1E, and
RAET1G; and Dako LSAB®2 System-HRP (Dako) for
ULBP2. The stain was visualized using DAB+ kit (3,3’-
Diaminobenzidine; Dako) and then lightly counterstained
with hematoxylin. The slides were covered and observed
under a light microscope (Axioplot, Carl Zeiss, Jena,
Germany). Negative controls were processed by omitting
the primary antibodies, and TMAs included colorectal
cancer positive control tissues [19].
Evaluation of IHC staining
For the assessment of NKG2DL staining, two scores
were assigned to each core: (a) the staining intensity
(no evidence of staining, 0; weak staining, 1+; moderate
staining, 2+; and strong positive staining in most cells, 3+)
and (b) the percentage of positively stained epithelial cells
(no cells staining positive, 0; less than 25% of cells staining
positive, 1+; 25–50% of cells staining positive, 2+; 50–75%
of cells staining positive, 3+; and more than 75% of cells
staining positive, 4+). An overall protein expression score
was calculated by multiplying the intensity and positivity
scores (overall score range, 0–12). The IHC staining score
was then dichotomized into low expression (≤ mean score
of cancer specimens) and high expression (> mean score
of cancer specimens). Slides were scored without any
clinical information, and the final immunostaining score
reported was the average of two independent pathologists,
both with experience in the analysis of tissue microarray.
Statistical analysis
Statistical analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago, IL). The statistical significance
of the differences in staining score of NKG2DLs in the
different groups was calculated by the Mann–Whitney
test and the Kruskal-Wallis test. Overall and disease-free
survival curves were generated by the Kaplan-Meier
method and the difference between the survival curves
was calculated by the log-rank test. The Cox proportional
hazards model was used for multivariate analysis to
determine independent significance of relevant clinical
covariates. In all cases, a p value < 0.05 was considered
statistically significant.
Results
Clinicopathologic characteristics of patient cohort
Table 1 summarizes patient clinicopathologic characteris-
tics. The overall mean age of patients was 40.6 ± 9.8 years
for low-grade CIN, 38.9 ± 11.2 years for high-grade CIN,
and 49.4 ± 11.7 years for cervical cancer. The distribution
of FIGO staging for the 200 cases of cervical cancer is as
follows: 138 stage I, 53 stage II, and 9 stage IV. The follow-
ing cell types were assigned according to World Health
Organization (WHO) criteria: 164 squamous cell carcin-
omas, 30 adenocarcinomas/adenosquamous carcinomas, 4
Table 1 Characteristics of patients
Variable Number %
Age (years) 42.58 ± 12.15a
Diagnostic category
Normal 541 46.4
Low-grade CIN 99 8.5
High-grade CIN 327 28.0
Cancer 200 17.1
FIGO stage
I 138 69.0
II 53 26.5
IV 9 4.5
Tumor gradeb
Well/Moderate 117 65.7
Poor 61 34.3
Cell type
SCC 164 82.0
AC/ASC 30 15.0
Others 6 3.0
Tumor size
≤ 4 cm 145 72.5
> 4 cm 55 27.5
Lymphovascular invasionc
Negative 95 64.6
Positive 52 35.4
Lymph node metastasisd
Negative 141 77.5
Positive 41 22.5
Chemoradiation responsee
Good 38 77.6
Bad 11 22.4
SCC antigenf
Negative 100 66.7
Positive 50 33.3
HPV test in CINg
Negative 39 11.5
Positive 300 88.5
CIN, cervical intraepithelial neoplasia; FIGO, International Federation of
Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC,
adenocarcinoma; ASC, adenosquamous carcinoma. amean ± standard
deviation, bcalculated only for the 178 cases with available information on
tumor grade, ccalculated only for the 147 cases with available information on
examined lymphovascular invasion, dcalculated only for the 182 cases with
available information on examined lymph nodes, ecalculated only for the 49
cases with available information on chemoradiation response, fcalculated only
for the 114 cases with available information on SCC antigen level, gcalculated
only for the 339 CIN cases with available information on HPV infection.
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carcinomas. HC2-confirmed HPV infection rate was 78.7%
(74/94) in low-grade CIN, 92.2% (226/245) in high-grade
CIN, and 93.9% (92/98) in cervical cancer.
Confirmation of NKG2DLs in cervical cancer cell lines
Expression of NKG2DLs was determined by flow cytomet-
ric assay using recombinant human NKG2D-Fc chimera
protein in cell cultures prior to IHC analysis for individual
NKG2DL expression in cervical cancer tissues. NKG2D-Fc
chimera protein binds to NKG2D through ligand-receptor
interaction on the cell surface, and it is detected by anti-Fc
antibody conjugated with fluorophores. As a result, using
NKG2D-Fc chimera protein in flow cytometric assay
allows us to confirm the expression and binding ability of
NKG2DLs even without a characterization of ligands. As
shown in Figure 1, expression of NKG2DLs was deter-
mined in six different cervical cancer cell lines (C-33A,
CaSki, HeLa, ME-180, SiHa and SUN-17). Five cancer cell
lines (all but C-33A) expressed NKG2DLs, which could
bind to NKG2D, supporting the hypothesis that cervical
cancers express NKG2DLs in vivo.
Expression of individual NKG2DLs in cervical neoplasias
We then performed IHC analysis of MICA/MICB,
ULBP1, ULBP2, ULBP3, RAET1E, and RAET1G in 200
cervical cancer specimens, 327 high-grade CINs, 99 low-
grade CINs, and 541 matched nonadjacent normal cervical
epithelial tissue samples. Representative immunohisto-
chemical expression of individual NKG2DLs are presented
in Figure 2. ULBP3 was expressed exclusively in the nucleus
in both tumor and normal epithelial cells, while the other
markers were expressed primarily in the cytoplasm, with
some cases also demonstrating weak nucleus staining
(Figure 2). Scoring results from the IHC analyses are sum-
marized in Table 2. The TMA contains 200 cases of cervical
cancer, however due to the complexity of sectioning and
staining, between 180 and 195 samples could be interpreted
for the individual marker. Invasive cervical cancer tissues
had higher MICA/B, ULBP1, and RAET1E expression than
CIN or normal cervical epithelial tissues (all p < 0.001). This
trend of progressively increasing MICA/B, ULBP1, and
RAET1E expression corresponded to the phases of cervical
cancer progression and was significant according to
Spearman’s rank correlation (ρ-value of 0.313 [p < 0.001],
0.285 [p < 0.001], or 0.136 [p < 0.001], respectively). ULBP2
and ULBP3 expression, on the other hand, was higher in
low-grade CIN than in normal epithelium but gradually
decreased in high-grade CIN and cervical cancer (p = 0.001
and p = 0.017, respectively).
Association of NKG2DLs
To determine the association between expression of
MICA/MICB, ULBP1, ULBP2, ULBP3, RAET1E, and
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Figure 1 Characterization of the binding of various human cervical cancer cell lines with human NKG2D Fc chimera. Various human
cervical cancer cells were incubated with recombinant human NKG2D chimera and then anti-Fc-PE. Characterization was performed via flow
cytometry. As a control, each kind of cell was stained with anti-Fc-PE antibodies.
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performed (Table 3). Cervical cancer lesions were
evaluated for co-expression between individual NKG2DLs.
MICA/B expression was significantly correlated with the
expression of ULBP1 (Spearman’s rho = 0.677, p < 0.001)
or ULBP2 (Spearman’s rho = 0.257, p < 0.001), whereas
MICA/B expression was not significantly correlated with
those of ULBP3 (Spearman’s rho = 0.119, p = 0.112),
RAET1E (Spearman’s rho = 0.044, p = 0.555), or RAET1G
(Spearman’s rho = −0.042, p = 0.574).
Prognostic significance of NKG2DL expression
Finally, to investigate the prognostic significance of the
expression of individual NKG2DLs in cervical cancer, we
studied the correlation of NKG2DL expression with
overall and disease-free survival. Clinicopathologic and
outcome information were available for all 200 cervical
cancer patients who were monitored for survival and
recurrence. Kaplan-Meier plots demonstrated that patients
with high MICA/B (Log-rank p = 0.027) or ULBP1
(Log-rank p = 0.009) expression and low RAET1E
(Log-rank p = 0.018) or RAET1G (Log-rank p = 0.029)
expression had significantly longer disease-free survival
time (Table 4, Figure 3A and B). When analyzed
individually for effect on overall survival, high ULBP1
expression predicted significantly longer survival time
(Log-rank p = 0.007) (Table 4, Figure 3D and E). In
particular, when survival of patients with expression
of high MICA/B/high ULBP1 was compared with those of
other patients, Kaplan-Meier analysis revealed a significant
difference in both disease-free (p < 0.001, Figure 3C) and
overall survival (p = 0.001, Figure 3F). A Cox multivariate
proportional hazards analysis showed that advanced stage
(hazard ratio = 3.60 [95% CI, 1.36–9.55], P = 0.010)
and lymph node metastasis (hazard ratio = 2.71 [95%
CI, 1.08–6.79], p = 0.032) were related to poor disease-freesurvival, whereas high ULBP1 (hazard ratio = 0.31 [95%
CI, 0.11–0.86], p = 0.024) and high MICA/B/high ULBP1
(hazard ratio = 0.16 [95% CI, 0.13–0.70], p = 0.015) expres-
sion was related to good disease-free survival (Table 2).
When analyzed for effect on overall survival, advanced
stage (hazard ratio = 2.77 [95% CI, 1.13–7.76], p = 0.025)
and high ULBP1 (hazard ratio = 0.27 [95% CI, 0.07–0.97],
p = 0.044) expression were significant independent prog-
nostic factors in multivariate analysis.
Discussion
Studies based on various in vivo models suggest that
the immune system not only protects the host from
early-stage tumors, but also promotes tumor growth
through a process described as immunoediting, immunos-
culpting or cancer immune system, which can result in the
outgrowth of more aggressive tumor cells via exposure to
immune effectors and loss of immunogenicity [18,20,21]. In
addition, these in vivo cancer models also strongly suggest
that the activating immune receptor NKG2D stimulates
anti-cancer immune responses [22-24]. Considering the fact
that many human primary tumors and tumor-derived cell
lines express NKG2DLs [12,16], a great deal of research is
currently focused on investigating the role of NKG2D in
host-mediated tumor immunity. Despite recent progress,
the biological functions of NKG2DLs are not yet fully
understood, and the clinicopathologic significance of these
ligands in cervical cancer has yet to be reported.
In the present study, we investigated NKG2DL expression
and further explored the clinical significance of NKG2DLs
by using samples from a large cohort of patients including
cervical cancer, precursor and corresponding normal
specimens. Immunohistochemistry analysis revealed that
MICA/B and ULBP1 were significantly upregulated in
cervical cancer tissues compared to their corresponding
normal tissues. Notably, higher MICA/B and ULBP1
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Figure 2 Immunohistochemical stains for MICA/MICB, ULBP1, ULBP2, ULBP3, RAET1E, and RAET1G on tissue microarrays. All photos are
at the same magnification. Bar: 50 μm.
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cervical carcinogenesis, increasing from normal cervical
tissue to progressively advanced stages of cervical cancer
precursors (low-grade and high-grade CIN) and ultimately
to invasive cancer. These findings suggest that MICA/B
and ULBP1 upregulation follows malignant transform-
ation in cervical carcinogenesis. Thus, not only can these
proteins be used as potential markers in treatment and
surveillance of cervical cancer, but they may also have
some utility in screening. Since their expression increases
even in early stages of cervical cancer, MICA/B and
ULBP1 expression can be used to identify precursor
lesions (i.e., CIN) that are at high risk of developing
invasive cervical cancer.In addition to the correlations between NKG2DL
expression levels and stages of cervical carcinogenesis,
NKG2DL expression was heterogeneous in primary
cancers, as not all of the ligands were highly expressed in
the same tumor. More specifically, MICA/B, ULBP1 and
RAET1E expression was significantly increased in cervical
cancer tissues, while ULBP2 and ULBP3 expression were
higher in low-grade CIN tissues, but lower in high-grade
CIN and cervical cancer tissues. Similar to our study,
Textor et al. demonstrated that NKG2DL MICA expression
was upregulated in squamous cervical carcinoma tissues
(n = 15) compared to CIN (n = 28) and normal ectocervical
tissues (n = 10) while ULBP2 was strongly expressed in
normal ectocervical tissues [14]. Although the mechanism
Table 2 IHC scores of NKG2DLs MICA/B, ULBP1, ULBP2, ULBP3, RAET1E, and RAET1G in 1,167 TMA specimens
Number % Mean
score
95% CI p value
Lower Upper
MICA/B Normal 457 45.2 4.83 4.62 5.04 <0.001
Low-grade CIN 90 8.9 4.89 4.53 5.25
High-grade CIN 270 26.7 6.30 6.00 6.61
Cancer 195 19.3 6.78 6.43 7.13
Total 1012 100.0 5.60 5.45 5.76
ULBP1 Normal 500 45.9 4.82 4.64 5.00 <0.001
Low-grade CIN 92 8.4 5.54 5.14 5.94
High-grade CIN 314 28.8 6.05 5.78 6.32
Cancer 183 16.8 6.66 6.27 7.04
Total 1089 100.0 5.54 5.40 5.68
ULBP2 Normal 458 43.5 3.47 3.30 3.65 0.001
Low-grade CIN 93 8.8 4.23 3.82 4.63
High-grade CIN 318 30.2 3.94 3.73 4.16
Cancer 184 17.5 3.71 3.40 4.02
Total 1053 100.0 3.72 3.60 3.84
ULBP3 Normal 455 44.0 5.22 5.02 5.41 0.017
Low-grade CIN 93 9.0 5.84 5.37 6.31
High-grade CIN 307 29.7 5.34 5.05 5.63
Cancer 180 17.4 4.91 4.56 5.26
Total 1035 100.0 5.26 5.11 5.40
RAET1E Normal 461 44.4 3.57 3.47 3.68 <0.001
Low-grade CIN 94 9.1 3.77 3.54 3.99
High-grade CIN 302 29.1 3.76 3.62 3.91
Cancer 181 17.4 4.38 4.12 4.65
Total 1038 100.0 3.79 3.71 3.87
RAET1G Normal 470 44.2 5.11 4.95 5.27 0.001
Low-grade CIN 95 8.9 5.17 4.83 5.50
High-grade CIN 314 29.5 4.61 4.39 4.82
Cancer 184 17.3 5.11 4.78 5.45
Total 1063 100.0 4.97 4.85 5.08
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and unclear at this time, it may be partially explained by
the following reasons. First, this heterogeneity may be due
to NKG2DLs having different promoters and NKG2D’s
ability to be expressed independently in response to
diverse stress response pathways. Secondly, evidence
of post-transcriptional regulation of NKG2DLs, including
the involvement of micro-RNAs (miR-20a, miR-93,
miR106b, miR-302d, miR-372, miR-373 and miR-520d), also
indicates that NKG2D expression is further differentially
regulated [25]. Lastly, some stimuli, such as DNA damage
response, have been reported to result in expression
of all NKG2DLs tested, while other stimuli have been
shown to induce expression of other specific NKG2DLs[26]. BCR/ABL, for example, regulates MICA, but not
ULBP1-2 in K562 cells, while histone deacetylase
inhibitor induces MICA, but not ULBP1-3 in hepatoma
cells [27,28].
Regardless of NKG2DL heterogeneity in expression,
our prognostic model indicates that the presence of
NKG2DLs is crucial for stimulating immune responses
against tumors. Our survival analysis indicates that the
high expression of NKG2DLs predicts a good prognosis,
with the combination of ULBP1 and MICA/B predicting
disease-free survival and ULBP1 independently predicting
both disease-free and overall survival with statistical
significance (Table 5). This is in agreement with a recent
report on MIC/ULBP/RAET expression in 462 primary
Table 3 Spearman’s rank correlation coefficient in cervical cancer specimens
MICA/B ULBP1 ULBP2 ULBP3 RAET1E RAET1G
Spearman’s correlation MICA/B ρ 1.000 .677 .257 .119 .044 -.042
p NA < .001 < .001 .112 .555 .574
n 195 183 181 179 181 182
ULBP1 ρ .677 1.000 .232 .140 .018 -.055
p < .001 NA .002 .068 .820 .476
n 183 183 174 171 169 170
ULBP2 ρ .257 .232 1.000 .333 -.119 -.107
p < .001 .002 NA < .001 .121 .162
n 181 174 184 176 172 174
ULBP3 ρ .119 .140 .333 1.000 .268 .158
p .112 .068 < .001 NA < .001 .038
n 179 171 176 180 172 173
RAET1E ρ .044 .018 -.119 .268 1.000 .616
p .555 .820 .121 < .001 NA < .001
n 181 169 172 172 182 179
RAET1G ρ -.042 -.055 -.107 .158 .616 1.000
p .574 .476 .162 .038 < .001 NA
n 182 170 174 173 179 184
NA, not applicable.
Table 4 Overall and disease-free survival analysis of NKG2DLs MICA/B, ULBP1, ULBP2, ULBP3, RAET1E, and RAET1G
Disease-Free Survival Time Overall Survival Time
Mean 95% CI Log-rank P Mean 95% CI Log-rank P
MICA/B
Low (n = 112) 127 112-141 0.027 146 133-158 0.181
High (n = 83) 164 150-178 169 155-183
ULBP1
Low (n = 106) 125 110-140 0.009 139 125-152 0.007
High (n = 77) 163 148-178 177 167-188
ULBP2
Low (n = 93) 144 127-160 0.279 165 152-178 0.640
High (n = 91) 148 134-163 155 141-169
ULBP3
Low (n = 79) 136 121-151 0.364 147 134-160 0.707
High (n = 101) 139 122-157 159 144-173
RAET1E
Low (n = 123) 157 144-170 0.018 163 151-175 0.935
High (n = 59) 116 96-137 149 135-164
RAET1G
Low (n = 104) 159 146-172 0.029 166 154-179 0.234
High (n = 80) 127 108-146 149 132-165
IHC staining scores of the NKG2DLs were dichotomized into low expression (≤ mean score of cancer specimens) and high expression (> mean score of
cancer specimens).
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Figure 3 Kaplan–Meier plots for overall (A, B, C) and disease-free (D, E, F) survival for patients categorized by MICA/B or ULBP1 expression.
Table 5 Cox proportional univariate and multivariate analysis of the association between prognostic variables and
overall and disease-free survival in cervical cancer
Disease-free Survival hazard ratio [95% CI], P value Overall Survival hazard ratio [95% CI], P value
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
FIGO stage 5.32 [2.75-10.30], <0.001 3.60 [1.36-9.55], 0.010 3.97 [1.65-9.54], 0.002 2.77 [1.13-7.76], 0.025
Tumor grade (poor) 1.65 [0.85-3.22], 0.137 NA 2.15 [0.89-5.21], 0.087 NA
Tumor size (>4 cm) 2.13 [1.09-4.14], 0.025 1.16 [0.47-2.90], 0.737 1.90 [0.78-4.65], 0.157 NA
LN metastasis 4.53 [2.14-9.61], <0.001 2.71 [1.08-6.79], 0.032 2.25 [0.77-6.59], 0.136 NA
HPV+ 0.68 [0.08-5.21], 0.710 NA 0.38 [0.048-3.10], 0.370 NA
MICA/B+ 0.43 [0.20-0.92], 0.032 0.54 [0.20-1.41], 0.213 0.53 [0.20-1.36], 0.189 NA
ULBP1+ 0.36 [0.16-0.80], 0.012 0.31 [0.11-0.86], 0.024 0.21 [0.06-0.73], 0.014 0.27 [0.07-0.97], 0.044
RAET1E+ 2.17 [1.12-4.2], 0.021 1.90 [0.84-4.32], 0.123 1.03 [0.41-2.60], 0.935 NA
RAET1G+ 2.09 [1.05-4.15], 0.034 1.62 [0.68-3.87], 0.275 1.69 [0.70-4.09], 0.240 NA
MICA/B+/ULBP1+ 0.11 [0.02-0.45], 0.002 0.16 [0.03-0.70], 0.015 0.026 [0.00-1.17], 0.060 NA
IHC staining scores of NKG2DLs were dichotomized into low (−) expression (≤ mean score of cancer specimens) and high (+) expression (> mean score of
cancer specimens).
FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; HPV, human papilloma virus; CI, confidence interval; NA, not applicable.
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MIC or RAET1G predicts improved patient survival [19].
Considering the fact that NKG2DLs are involved in
anti-cancer immune responses, an association between
high expression of NKG2DLs and good prognosis is
quite reasonable. Thus, when identifying patients with
cervical cancer at increased risk of tumor invasion
and/or progression, examining the expression levels of
ULBP1 or MICA/B via IHC may have utility. Furthermore,
these findings all emphasize that NKG2DLs have important
functions in the biological mechanism underlying the
development and/or growth of human cervical cancer.
However, in contrast to our results, recent studies by
Li et al. demonstrated that high expression of MICA/B
and ULBP2 is associated with poor prognosis in ovarian
cancer patients [29]. This, together with our results,
indicates that although NKG2DLs induce anti-cancer
immune responses, the extent of these responses can
markedly differ depending on the type of cancer. Such
differences arise because NKG2DLs depend heavily on the
tissue microenvironment where an assemblage of interac-
tions by signals of cellular receptors and cytokines take
place [30]. Since these interactions differ depending on
the type of the cancer, different NKG2D responses are
elicited [31,32]. Thus, not only are NKG2DLs expressed in
response to different cancer-related pathways, but also
their expression is highly heterogeneous.
Intriguingly, although the results of our multivariate
analysis were not significant, in univariate analysis, high
RAET1E or RAET1G expression was associated with
poor disease-free survival (Table 5). This finding agrees
partially with a recent report on NKG2DL expression in
357 ovarian cancers, wherein high expression levels of
ULBP2 and RAET1G was inversely correlated to the
disease survival [33]. The lack of complete agreement
may be due to the use of a different cancer type.
However, more importantly, it can be explained by a
study performed by Cao et al., in which RAET1E was
able to produce soluble protein lacking a transmembrane
region that weakened NKG2D-mediated NK cell cytotox-
icity to tumor cells, despite that RAET1E and RAET1G
contain both transmembrane and cytoplasmic domains
[34]. Given the results of Cao et al.’s study and the fact
that many isoforms were also stained during RAET1E
and RAET1G IHC staining, it is possible that high
RAET1E and RAET1G expression may be associated
with poor prognosis.
Conclusions
Overall, the expression of several NKG2DLs, namely
MICA/B, ULBP1, and RAET1E, were increased in cervical
cancer patients. In multivariate analysis, FIGO stage, lymph
node metastasis, high ULBP1 expression and high com-
bined MICA/B and ULBP1 expression were independentpredictors of good prognosis. These findings all underscore
the importance of NKG2D function in cervical tumor
progression and cancer immunosurveillance, and suggest
that combinatorial analysis of NKG2DL expression may
assist in realizing improved prognostic classification of
cervical and other carcinomas.
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